focus -WSS

focus

author：hotspot 2025-09-06 03:17:17 - browse：4455

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

focus

WSS

Dairy farmers resist CDC push for PPE against bird flu virus

'Make People Better': The CRISPR babies story you probably don't know

Elevance, private equity launch primary care company

Medicare says breakthrough device reimbursement rule to come by summer

How to protect patients from sexual assault

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

focus

Wikipedia

Bright Health sells Medicare Advantage business to Molina

The (many) problems with a new study criticizing cancer screening

New air purifier tech could be key to improving indoor air quality

Medicaid rebukes states for mistakenly disenrolling children

The high cost of giving birth even with insurance

AstraZeneca chief proposes a novel edit to the drug pricing bill

New air purifier tech could be key to improving indoor air quality

CDC wastewater surveillance dashboard to track bird flu hotspots

Malaria cases in Florida and Texas: Here’s what you need to know

House transparency, PBM reform bill gains bipartisan support

entertainment

Crinetics acromegaly drug succeeds in late

Brain worms: The science behind RFK Jr.'s parasitic infection

Crinetics acromegaly drug succeeds in late

House transparency, PBM reform bill gains bipartisan support

Advances in CAR

Listen: Biogen's potential pivot, & Illumina's next chapter

leisure time

entertainment

focus

hotspot